Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction

Yukihito Sato; Takashi Kuragaichi; Shunsuke Saga; Hiroyuki Nakayama; Tomoe Obata; Mitsumasa Watanabe; Kie Fujikura; Masatoki Watanabe; Ken-ichiro Hata; Hajime Ohgushi

doi:10.1253/circrep.CR-21-0091

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Safety of Intravenous Autologous Bone Marrow-Derived Mesenchymal Cell Transplantation in 5 Patients With Reduced Left Ventricular Ejection Fraction

Yukihito Sato, Takashi Kuragaichi, Shunsuke Saga, Hiroyuki Nakayama, Tomoe Obata, Mitsumasa Watanabe, Kie Fujikura, Masatoki Watanabe, Ken-ichiro Hata, Hajime Ohgushi

著者情報

キーワード: Heart failure, Mesenchymal cell, Regeneration therapy

ジャーナルオープンアクセス HTML 早期公開

論文ID: CR-21-0091

DOI https://doi.org/10.1253/circrep.CR-21-0091

この記事には本公開記事があります。

The final version of this article is now available: Vol. 3 (2021), No. 9 pp. 550-554

詳細

抄録

Background:Although intracardiac injection or intracoronary delivery of mesenchymal stem cells (MSCs) has been reported, there have been few studies on the intravenous injection of MSCs, particularly in Japan.

Methods and Results:Five patients with left ventricular ejection fraction (LVEF) ≤45% received 1.0×10⁸MSCs intravenously. The procedure did not induce significant changes in vital signs. One patient had an elevated body temperature after 1 day, but recovered spontaneously. Laboratory tests remained normal for 1 month after cell delivery. Computed tomography was performed after 1–2 years, and there was no evidence of malignancy.

Conclusions:In this pilot study of patients with reduced LVEF, intravenous MSC delivery had no adverse effects.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）